Colonial Trust Advisors bought a new stake in Humana Inc (NYSE:HUM) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 55,551 shares of the insurance provider’s stock, valued at approximately $13,780,000. Humana comprises about 2.1% of Colonial Trust Advisors’ holdings, making the stock its 13th biggest position.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Fieldpoint Private Securities LLC acquired a new stake in shares of Humana during the 3rd quarter worth approximately $115,000. American Beacon Advisors Inc. acquired a new stake in shares of Humana during the 4th quarter worth approximately $122,000. ClariVest Asset Management LLC acquired a new stake in shares of Humana during the 3rd quarter worth approximately $144,000. YorkBridge Wealth Partners LLC grew its holdings in shares of Humana by 99.0% during the 4th quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock worth $159,000 after purchasing an additional 297 shares in the last quarter. Finally, Daiwa SB Investments Ltd. grew its holdings in shares of Humana by 44.9% during the 4th quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock worth $176,000 after purchasing an additional 220 shares in the last quarter. 96.36% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have recently weighed in on HUM. Zacks Investment Research lowered Humana from a “buy” rating to a “hold” rating in a report on Tuesday, March 13th. JPMorgan Chase & Co. lifted their price objective on Humana from $253.00 to $271.00 and gave the stock a “neutral” rating in a report on Monday, February 12th. Deutsche Bank lifted their price objective on Humana from $259.00 to $270.00 and gave the stock a “hold” rating in a report on Friday, February 9th. Jefferies Group upgraded Humana from a “hold” rating to a “buy” rating and set a $221.00 target price for the company in a research report on Friday, January 12th. Finally, Cantor Fitzgerald restated a “hold” rating and set a $230.00 target price on shares of Humana in a research report on Tuesday, December 5th. Eight analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $270.47.
In other news, insider M Todoroff Christopher sold 16,389 shares of the business’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $273.37, for a total transaction of $4,480,260.93. Following the completion of the sale, the insider now owns 13,447 shares in the company, valued at $3,676,006.39. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Bruce D. Broussard sold 14,075 shares of the business’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $274.32, for a total value of $3,861,054.00. Following the sale, the chief executive officer now owns 113,896 shares of the company’s stock, valued at approximately $31,243,950.72. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,660 shares of company stock valued at $8,668,218. Corporate insiders own 0.60% of the company’s stock.
Humana stock opened at $270.81 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.85. Humana Inc has a 52-week low of $203.48 and a 52-week high of $293.35. The stock has a market capitalization of $37,172.01, a price-to-earnings ratio of 16.24, a price-to-earnings-growth ratio of 1.46 and a beta of 0.95.
Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. Humana had a return on equity of 16.13% and a net margin of 4.55%. The firm had revenue of $13.19 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same quarter in the previous year, the company posted $2.34 EPS. The business’s revenue for the quarter was up 2.4% compared to the same quarter last year. equities research analysts expect that Humana Inc will post 13.84 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Friday, March 30th will be given a $0.50 dividend. This is an increase from Humana’s previous quarterly dividend of $0.40. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $2.00 annualized dividend and a yield of 0.74%. Humana’s payout ratio is presently 9.59%.
Humana announced that its board has authorized a share repurchase program on Thursday, December 14th that permits the company to buyback $3.00 billion in shares. This buyback authorization permits the insurance provider to reacquire shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.
WARNING: “55,551 Shares in Humana Inc (HUM) Purchased by Colonial Trust Advisors” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/03/22/55551-shares-in-humana-inc-hum-purchased-by-colonial-trust-advisors.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.